P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES
Main Authors: | Fabian Lang, Susan Branford, Joseph P. Lyssikatos, Helen Collins, Andreas Hochhaus |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000969636.32603.d4 |
Similar Items
-
Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
by: Francesca Carofiglio, et al.
Published: (2020-06-01) -
The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
by: Erin Clapper, et al.
Published: (2021-05-01) -
Simvastatin enhances the efficacy of Bcr-Abl tyrosine kinase inhibitor nilotinib in chronic myeloid leukemia.
by: Koh, Yanqing.
Published: (2011) -
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
by: Aghel N, et al.
Published: (2017-08-01) -
Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
by: Yihua Wang, et al.
Published: (2023-01-01)